Overview

CJC-1295 with DAC is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) for enhanced stability. This 2mg format offers researchers a smaller-scale option for studies requiring extended hormone stimulation.

The DAC addition enables prolonged half-life, allowing a more sustained presence in the bloodstream compared to non-DAC peptides.

Research Interest

CJC-1295 with DAC is valued in experimental endocrinology for its ability to promote growth hormone release, which in turn influences IGF-1 production. Studies have examined its impact on metabolic regulation, tissue repair, and hormonal balance in research models.

The 2mg presentation is suitable for projects requiring smaller dosing increments or pilot studies before scaling up research volumes.

How It Works

By binding to pituitary receptors, CJC-1295 with DAC mimics natural GHRH signaling. The DAC modification allows the peptide to attach to albumin, protecting it from rapid breakdown and extending its activity window to several days in animal studies.

Potential Study Areas

• Long-acting hormone release modeling
• Endocrine regulation experiments
• Comparative DAC vs non-DAC evaluations
• Synergy with GHRP compounds
• Peptide stability and pharmacokinetics research

Chemical Data

Sequence: Modified GHRH 1-29 with DAC
Molecular Formula: C165H269N47O46
Molecular Weight: ~3647.20 g/mol

The DAC moiety enhances peptide–protein interaction, leading to sustained systemic presence in research subjects.

Storage & Handling

Store lyophilized CJC-1295 with DAC at −20°C in a dry, dark environment. After reconstitution, refrigerate at 2–8°C and use within established study timelines. Avoid multiple freeze–thaw cycles.

For Research Use Only

CJC-1295 with DAC 2mg is intended solely for scientific investigation by qualified personnel. Not for human or veterinary use.

• GHRH – Wikipedia
• Drug Affinity Complex – Wikipedia
• Albumin – Wikipedia